Trintellix release date?

See the DrugPatentWatch profile for Trintellix

Trintellix, known generically as vortioxetine, was first approved by the U.S. Food and Drug Administration (FDA) in October 2013. [1] The medication is indicated for the treatment of major depressive disorder (MDD) in adults. [1]

When did Trintellix become available in pharmacies?

Following its FDA approval in October 2013, Trintellix became available for prescription and dispensing by pharmacies shortly thereafter. [1]

What is the active ingredient in Trintellix?

The active ingredient in Trintellix is vortioxetine. [1]

Who manufactures Trintellix?

Trintellix is manufactured by Takeda Pharmaceuticals and Lundbeck. [2]

How does vortioxetine work?

Vortioxetine is a multimodal antidepressant. Its exact mechanism of action is not fully understood, but it is believed to involve the inhibition of serotonin reuptake and modulation of various serotonin receptors. [1]

What is the patent status for Trintellix?

Information regarding specific patents for Trintellix and their expiration dates can be found on DrugPatentWatch.com. [3] Patent expiry dates are crucial as they determine when generic versions of a drug can enter the market. [3]